Combined Antibody Screening for Celiac and Diabetes Evaluation
CASCADE
1 other identifier
observational
64,410
1 country
1
Brief Summary
The CASCADE Study (Combined Antibody Screening for Celiac and Diabetes Evaluation) is an observational study whose primary goal is to show that population-based screening for advanced prediction of type 1 diabetes (T1D) and celiac disease (CD) is feasible to prevent diabetic ketoacidosis (DKA), improve celiac disease diagnosis, and ultimately gain public health acceptance to facilitate future prevention. It has two arms, a Birth Cohort and a Kids (cross sectional) Cohort.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2020
CompletedFirst Submitted
Initial submission to the registry
December 16, 2020
CompletedFirst Posted
Study publicly available on registry
December 21, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
ExpectedDecember 21, 2020
December 1, 2020
2 years
December 16, 2020
December 16, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Diagnosis of Type 1 Diabetes
5 years
Diagnosis of Celiac Disease
5 years
Secondary Outcomes (1)
Severity of disease at diagnosis
5 years
Study Arms (2)
Birth Cohort
Newborns less than 8 months old and born in the state of Washington.
Kids Cohort
Children ages 4-7 years and born in the state of Washington.
Interventions
Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.
Eligibility Criteria
Newborns and school aged children in the state of Washington.
You may qualify if:
- Child must be between 0 to 8 months in age or between 4 to 7 years in age. Child must be born in the state of Washington.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pacific Northwest Research Institutelead
- University of Exetercollaborator
Study Sites (1)
Pacific Northwest Research Institute
Seattle, Washington, 98122, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
William Hagopian, MD PhD
Pacific Northwest Research Institute
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of Diabetes Program
Study Record Dates
First Submitted
December 16, 2020
First Posted
December 21, 2020
Study Start
December 1, 2020
Primary Completion
December 1, 2022
Study Completion (Estimated)
June 1, 2026
Last Updated
December 21, 2020
Record last verified: 2020-12